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Abstract
Background: Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with
hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplantation.
Early diagnosis and therapy has been shown to improve outcomes, but reaching a definitive diagnosis quickly can
be problematic. Recently, galactomannan testing of bronchoalveolar lavage (BAL) fluid has been investigated as a
diagnostic test for IPA, but widespread experience and consensus on optical density (OD) cut-offs remain lacking.
Methods: We performed a prospective case-control study to determine an optimal BAL galactomannan OD cutoff
for IPA in at-risk patients with hematological diagnoses. Cases were subjects with hematological diagnoses who
met established definitions for proven or probable IPA. There were two control groups: subjects with
hematological diagnoses who did not meet definitions for proven or probable IPA and subjects with non-
hematological diagnoses who had no evidence of aspergillosis. Following bronchoscopy and BAL, galactomannan
testing was performed using the Platelia Aspergillus seroassay in accordance with the manufacturer’s instructions.
Results: There were 10 cases and 52 controls. Cases had higher BAL fluid galactomannan OD indices (median 4.1,
range 1.1-7.7) compared with controls (median 0.3, range 0.1-1.1). ROC analysis demonstrated an optimum OD
index cutoff of 1.1, with high specificity (98.1%) and sensitivity (100%) for diagnosing IPA.
Conclusions: Our results also support BAL galactomannan testing as a reasonably safe test with higher sensitivity
compared to serum galactomannan testing in at-risk patients with hematological diseases. A higher OD cutoff is
necessary to avoid over-diagnosis of IPA, and a standardized method of collection should be established before
results can be compared between centers.
Background
Invasive pulmonary aspergillosis (IPA) is a major cause
of morbidity and mortality in immunocompromised
patients, particularly those with hematological malignan-
cies in the setting of profound neutropenia and/or
hematopoietic stem cell transplantation [1]. Early diag-
nosis and therapy of IPA has been shown to improve
outcomes [2], but reaching a definitive diagnosis quickly
can be problematic in view of the lack of an exceptional
diagnostic test, even withi m p r o v e dg u i d e l i n e sa n d
newer test kits such as the Platelia Aspergillus seroassay
(Bio-Rad Laboratories, Hercules, California, USA) and
Fungitell 1,3 beta-D-glucan chromogenic assay (Associ-
ates of Cape Cod Inc., East Falmouth, Massachusetts,
USA) [3,4].
Recently, investigators have explored the possibility of
performing galactomannan testing on bronchoalveolar
lavage (BAL) fluid samples from diverse patient popula-
tions [5-10]. Although invasive, BAL is associated with
fewer complications than tissue biopsy, and BAL galac-
tomannan testing appears to be more sensitive (60% -
100%) and specific (82% - 100%) than serum galacto-
mannan testing for immunocompromised patients
[5,6,8-10]. Two cutoff BAL galactomannan optical den-
sity (OD) indices have been proposed - ≥0.5 [5] and
≥1.0 [6-10] - although the amount of sterile saline
instilled per BAL varied (40 ml to 150 ml) between stu-
dies, and few studies had well-defined negative controls.
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We attempted to determine an optimal BAL galacto-
mannan OD cutoff for IPA in at-risk patients with
hematological diagnoses in a prospective case-control
study.
All study subjects were recruited from our institute - a
997-bed tertiary acute-care hospital - between 1 Septem-
ber 2007 and 18 June 2009. The study schematic is
shown in Figure 1. Cases were subjects with hematologi-
cal diagnoses who matched the revised definitions for
proven or probable IPA established by the European
Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group (EORTC/
MSG) [3], without the use of BAL galactomannan
results. A single serum galactomannan OD cutoff of ≥
0.7 was considered positive if retesting of the original
sample gave the same result. At our institute,
bronchoscopy for the diagnosis of lower respiratory
tract invasive fungal disease (IFD) is performed only
when a patient has host factors and clinical features as
defined by EORTC/MSG [3], but the initial serum galac-
tomannan testing using the Platelia Aspergillus seroassay
is negative. Serum galactomannan testing is performed
twice weekly for at-risk patients.
Controls were recruited from among other patients
requiring bronchoscopy for diagnostic reasons. There
were two control groups to determine if the BAL galac-
tomannan test results differed among patients with or
without haematological diagnoses:
1. Subjects with hematological diagnoses satisfying
EORTC/MSG host factors criteria [3] who either:
a. Did not meet EORTC/MSG criteria for possi-
ble IFD OR
Figure 1 Study schematic.
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but had an alternative confirmed pulmonary
diagnosis other than IPA.
2. Subjects with non-hematological diagnoses who
were not diagnosed with any form of aspergillosis.
Exclusion criteria included the use of piperacillin/tazo-
bactam at the time of bronchoscopy as well as pro-
longed usage (more than 1 week) of any antifungal
agent that was active against Aspergillus spp. prior to
bronchoscopy.
BAL fluid samples were obtained by wedging the tip
of the bronchoscope against the bronchus leading to the
affected bronchopulmonary segment of maximal radio-
graphic involvement, followed by instillation and aspira-
tion of 40 to 60 ml aliquots of 0.9% sterile saline. Up to
10 ml of the first aliquot was sent for galactomannan
testing. Other microscopy and microbiological tests
were performed where ordered by the primary physi-
cians. Transbronchial lung biopsies were performed
where possible.
Galactomannan testing was performed on one sample
of the BAL fluid per subject by investigators blinded to
subject diagnoses and clinical characteristics. The Plate-
lia Aspergillus seroassay was used in a HEPA-filtered
biosafety cabinet according to the manufacturer’s
instructions. In brief, 300 μl of each BAL fluid sample
was added to 100 μl of treatment solution, boiled for 3
minutes, and centrifuged at 10,000 g for 10 minutes. 50
μl each of supernatant and conjugate were mixed and
incubated in microtiter plates pre-coated with monoclo-
nal antibody EB-A2 for 90 min at 37°C. Wells were
washed and incubated in the dark with 200 μlo fc h r o -
mogen solution for 30 minutes. Reactions were stopped
and absorbance at 450 and 620 nm read using a plate-
reader. Positive and negative controls (provided in the
kit) were included in each assay. Results were recorded
as an index relative to the OD of the cut-off control,
and retesting of the BAL samples were performed if the
OD index was ≥ 0.5. The optimal galactomannan OD
index cutoff was determined by ROC analysis using
STATA 10.1.
The institutional ethics committee approved this study
and written informed consent was obtained from all
subjects.
Results
There were a total of 10 cases (1 proven and 9 probable
IPA) and 52 controls (Figure 1). Four subjects with possi-
ble IFD but no definitive pulmonary diagnosis were
excluded from the study after enrolment. Demographic,
clinical and laboratory characteristics of cases and controls
are shown in Table 1, while the relevant individual charac-
teristics of cases are shown in Additional file 1: Table S1.
Four cases had concomitant serum galactomannan OD
index of ≥ 0.7 after initial negative tests, four cases had
Aspergillus hyphae seen on cytology of BAL fluid - one
also had positive BAL cultures for Aspergillus fumigatus,
and three cases had acute-angle branching hyphae with
tissue invasion seen on transbronchial lung biopsy. Nine
cases had already received empiric anti-Aspergillus therapy
prior to bronchoscopy, and their BAL fungal cultures were
negative (Additional file 1: Table S1). Median time from
the appearance of CT changes corresponding to EORTC
criteria for IFD [3] to bronchoscopy was 3.5 days (range 1
to 6 days). This corresponded with the time between
initiation of anti-Aspergillus therapy and bronchoscopy
with the exception of the final case, where therapy was
initiated after bronchoscopy.
Four subjects in control group 1 met EORTC/MSG cri-
teria for possible IPA with dense nodules visualized on
Table 1 Demographic, clinical and laboratory
characteristics of the study subjects.
Cases
(n = 10)
Control 1
a
(n = 17)
Control 2
b
(n = 35)
Median Age, years (Range) 35 (9 - 89) 43 (19 - 75) 63 (28 - 81)
Male gender (%) 8 (80.0) 13 (76.5) 24 (68.6)
Allogenic stem-cell
transplantation (%)
2 (20.0) 8 (47.1) 0 (0.0)
Neutropenia (%)
c 9 (90.0) 11 (64.7) 0 (0.0)
Serum galactomannan
testing:
- Number tested (%) 10 (100.0) 11 (64.7) 1 (2.9)
- Median OD index
(range)
d
0.3 (0.1 - 1.8) 0.1 (0.0 - 0.2) 0.2
BAL galactomannan testing:
- Median OD index (range) 4.1 (1.1 - 7.7) 0.2 (0.1 - 1.0) 0.4 (0.1 - 1.1)
- OD index ≥ 0.5 (%) 10 (100) 3 (17.6) 11 (31.4)
BAL fungal cultures (%): 10 (100) 17 (100) 18 (51.4)
- Candida spp. (%) 1 (10.0) 6 (35.3) 6 (33.3)
- Aspergillus spp. (%) 1 (10.0) 0 (0.0) 0 (0.0)
Primary pulmonary
diagnoses:
- IPA (%) 10 (100.0) 0 (0.0) 0 (0.0)
- Bacterial pneumonia (%) 0 (0.0) 4 (23.5) 14 (40.0)
- Lung cancer (%) 0 (0.0) 0 (0.0) 12 (34.3)
- Graft vs. host disease (%) 0 (0.0) 5 (29.4) 0 (0.0)
- Viral pneumonitis (%) 0 (0.0) 2 (11.8) 0 (0.0)
- Interstitial lung
disease (%)
0 (0.0) 0 (0.0) 3 (8.6)
- Others (%) 0 (0.0) 6 (35.3) 6 (17.1)
a Controls with underlying hematological diseases meeting EORTC/MSG host
factors criteria for invasive fungal disease [3].
b Controls with no underlying hematological diseases.
c Absolute neutrophil count < 500/mm
3
d Highest serum galactomannan OD index within two weeks of bronchoscopy,
if test was performed.
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sent for all - one had nocardiosis, one had Mycobacter-
ium abscesses infection, one had mucormycosis, and the
last had chronic pulmonary graft-versus-host disease.
None of the four had BAL galactomannan OD indices
exceeding 0.5, and three recovered without anti-Asper-
gillus therapy. The patient with mucormycosis died
from subsequent gram-negative septicemia. CT features
for the other subjects in this group comprised mainly
pulmonary ground-glass infiltrates and/or consolidative
changes. Only 11 (64.7%) subjects in control group 1
underwent serum galactomannan testing as the others
were not considered at-risk for IFD.
Fourteen (26.9%) control subjects had BAL galacto-
mannan OD indices that were ≥ 0.5. (Figure 1A) There
was no common pulmonary diagnosis among them.
BAL fungal culture was performed for 10 of these sub-
jects, with Candida spp. isolated from seven samples.
Thirteen did not receive anti-Aspergillus therapy and
recovered uneventfully. The last was prescribed empiric
caspofungin for persistent febrile neutropenia.
Subjects in control group 2 tended to have higher
BAL galactomannan OD indices (Figure 2A) compared
to control group 1 subjects, but this was not statistically
significant (p = 0.09). Combining the results of both
groups resulted in a median BAL galactomannan OD
index of 0.3 (range 0.1 - 1.1). In this case, the optimum
OD index cutoff was ≥ 1.1 based on ROC analysis (Fig-
ure 2B), yielding a sensitivity and specificity of 100.0%
(95%CI: 72.2% - 100%) and 98.1% (95%CI: 89.9% -
99.7%) respectively, and corresponding positive and
negative predictive values of 90.9% and 100% respec-
tively. Lowering the cutoff to ≥ 0.5 would result in
significantly reduced specificity of 71.2% (95%CI: 59.8%
- 83.2%), with corresponding positive and negative pre-
dictive values of 41.7% and 100% respectively.
No subject suffered significant adverse events from
bronchoscopy.
Discussion
Our study supports a higher galactomannan OD index
cutoff (1.1) when using the Platelia Aspergillus seroassay
on BAL fluid samples. This figure is higher than cutoffs
proposed by others in certain well-defined patient popu-
lations [6-8,10], but the control subjects in our study are
more heterogeneous, and may better represent a more
diverse patient population. The results also support BAL
galactomannan testing as a reasonably safe test with
potentially higher sensitivity compared to serum galacto-
mannan testing in at-risk patients with hematological
diseases [6,7,10].
In the four cases with both positive serum and BAL
galactomannan, the serum OD indices were lower than
BAL OD indices, and time to positivity was longer for
the former. This mirrored the results seen in an in vitro
rabbit model of IPA, where the discordance was attribu-
ted to the time taken by advancing hyphae to breach
the alveolar-capillary barrier [11].
False-positive BAL galactomannan tests have been
reported for patients with airways colonized by either
Aspergillus spp. or Penicillium spp. [8,9], but neither was
cultured from the BAL fluid of our controls with high OD
indices. Unlike the results of the Florida investigators, none
of our non-immunocompromised subjects had OD indices
exceeding 1.1, but our patient cohort was smaller [7].
One control had pulmonary mucormycosis and a low
BAL galactomannan OD index. This particular case
highlights the major deficiency of a galactomannan-
based diagnostic algorithm: that the diagnosis of other
emerging invasive moulds - albeit rare at present - may
be delayed or missed.
There are several limitations to our study. Firstly, the
number of subjects - particularly cases - is small, and this
may affect the distribution of results. Secondly, broncho-
scopy was only performed up to six days after
Figure 2 Bronchoalveolar lavage fluid galactomannan optical
density indices among cases and controls. Figure 2A.
Distribution of bronchoalveolar lavage (BAL) fluid galactomannan
optical density (OD) indices among cases and controls. Figure 2B
Receiver operating characteristic (ROC) analysis plot of BAL
galactomannan OD indices among cases and controls.
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immediate BALs [12]. Galactomannan testing is only per-
formed twice weekly at our institute, and we believed it
would be unethical to subject patients to the small but
real risks of bronchoscopy if mycological evidence could
be derived from serum galactomannan testing performed
at the time when clinical features of IPA are present
(there were three such patients during the study period).
In early IPA, it is possible that the BAL galactomannan
OD index may be lower than our proposed cutoff.
Thirdly, OD measurements are dependent on the con-
centration of the galactomannan antigen, which in BAL
fluid may be highly variable, being dependent on multiple
factors including the amount of saline instilled during
bronchoscopy, the area that is washed, time spent doing
the lavage, and the amount of fluid retrieved. Our
bronchoscopists instilled either 40 or 60 ml each time (all
cases received 60 ml), and this difference may add varia-
bility to the results. The amount of sterile saline instilled
varied significantly (40 to 150 ml) between studies [5-10],
suggesting that the results - although similar - may not
be comparable or extrapolated to other centers.
We are aware that standardizing BAL sampling is dif-
ficult especially given different clinical settings and
patient sizes - 40 to 60 ml of saline instillation would be
too much for a young child, but in an adult, occasionally
there may be insufficient amount of fluid retrieved for
testing. Nevertheless, standardization is important for
inter-institutional comparisons, and for inclusion of
BAL galactomannan testing OD cut-offs into interna-
tional guidelines.
Conclusions
In conclusion, our study demonstrates that BAL galacto-
mannan testing is a safe and useful adjunct in the diag-
nosis of IPA. A higher cutoff for BAL as compared to
serum galactomannan testing is necessary, however, to
avoid over-diagnosis of IPA. A standardized method of
collection should also be established before results can
be comparable between centers. This should hopefully
lead to better outcomes for our vulnerable patients.
Additional file 1: Table S1 - Clinical characteristics of cases of
proven/probable invasive pulmonary aspergillosis. Clinical
characteristics of individual cases of proven/probable invasive pulmonary
aspergillosis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
44-S1.DOC]
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